Financing HIV/AIDS Care: a Quilt with Many Holes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
View the Ryan White HIV/AIDS Program
F:\COMP\PHSA\PHSA-MERGED.XML 1351 PUBLIC HEALTH SERVICE ACT Sec. 2602 PUBLIC HEALTH SERVICE ACT [As Amended Through P.L. 114–113, Enacted December 18, 2015] øReferences in brackets ø¿ are to title 42, United States Code¿ TITLE XXVI—HIV HEALTH CARE SERVICES PROGRAM 1 PART A—EMERGENCY RELIEF FOR AREAS WITH SUBSTANTIAL NEED FOR SERVICES 2 Subpart I—General Grant Provisions SEC. 2601. ø300ff–11¿ ESTABLISHMENT OF PROGRAM OF GRANTS. (a) ELIGIBLE AREAS.—The Secretary, acting through the Ad- ministrator of the Health Resources and Services Administration, shall, subject to subsections (b) through (c), make grants in accord- ance with section 2603 for the purpose of assisting in the provision of the services specified in section 2604 in any metropolitan area for which there has been reported to and confirmed by the Director of the Centers for Disease Control and Prevention a cumulative total of more than 2,000 cases of AIDS during the most recent pe- riod of 5 calendar years for which such data are available. (b) CONTINUED STATUS AS ELIGIBLE AREA.—Notwithstanding any other provision of this section, a metropolitan area that is an eligible area for a fiscal year continues to be an eligible area until the metropolitan area fails, for three consecutive fiscal years— (1) to meet the requirements of subsection (a); and (2) to have a cumulative total of 3,000 or more living cases of AIDS (reported to and confirmed by the Director of the Cen- ters for Disease Control and Prevention) as of December 31 of the most recent calendar year for which such data is available. -
Chronic Immune Activation Is the Cause of AIDS: Implication of Treatment in the Developing World
Journal of Human Virology & Retrovirology Chronic Immune Activation is the Cause of AIDS: Implication of Treatment in the Developing World Opinion Abstract Volume 2 Issue 2 - 2015 Overwhelming number of evidence suggests that chronic immune system activation and dysregulation is responsible for progression into AIDS. Levels of activation Olga Malykhina* Liberal Arts and Sciences department, Devry University, markers on CD8+ and CD4+ T cells and other markers of activated immune response USA correlate with progression to AIDS. The uncontrolled inflammatory response has been associated with damage of lymphoid organs and the gastrointestinal mucosa; *Corresponding author: Olga Malykhina, Devry thus, further affecting T cell homeostasis and causing bacterial translocation, University visiting professor, 3300 N Campbell Ave, respectively. Immune system activation persists even after viral loads have been Chicago, IL, 60618, USA, Tel: 614-313-6343; Email: suppressed with antiretroviral therapy, which has been associated with increased [email protected] morbidity and mortality of patients. On the other hand, natural primate hosts of SIV display very little immune activation and do not progress to AIDS. Several studies Received: January 23, 2015 | Published: February 05, 2015 have been performed with immune suppressors and modifiers on HIV patients with varying degrees of success. The immune modifier that showed the most promise of being globally accessible and affordable HIV treatment is a probiotic. Probiotic treatment studies demonstrated safety and efficacy in maintaining T cell homeostasis of HIV-infected individuals. The probiotic also has the potential of being genetically manipulated to increase its effectiveness. An effective probiotic treatment for HIV infections has the potential of being grown locally in resource limited regions and by the users themselves; therefore, reducing cost of HIV treatment and prolonging the health of HIV-infected individuals. -
Hiv Single Pill Sustained Efficacy at 48 Weeks1,2
Discover this journal online at wileyonlinelibrary.com/journal/hiv single pill sustained efficacy at 48 weeks1,2 The first PI-based single tablet regimen (STR) for HIV-1 patients HIV MEDICINE EFFICACY RESISTANCE TOLERABILITY High virologic suppression** Contains darunavir, which Renal and bone safety at 48 weeks1,2 has a known high genetic profile consistent with 1 1,2 HIV barrier to resistance TAF and cobicistat For treatment- For treatment- Volume 19, Volume Supplement 2, April 2018, 1–160 Pages naïve patients* experienced patients‡ who may benefit from who may benefit from MEDICINE Symtuza’s resistance Symtuza’s resistance and efficacy profile, in and tolerability profile, a convenient STR1,2 in a convenient STR1,2 Volume 19, Supplement 2, April 2018 ISSN 1464–2662 SYMTUZASYMTUZA is indicated for the treatment of humahumann immunodeficiency virus typee 1 (HIV-1) infection in adults and adolescents (aged(aged 12 years and older with bodyy weight at least 40 kg).3 EDITORS Genotypic testing should guide the use of Symtuza.3 Brian Gazzard Jens Lundgren SYMTUZA® 800 mg/150 mg/200 mg/10 mg film-coated tablets monitoring with underlying chronic hepatitis, cirrhosis, pre-treatment transaminase elevations, PRESENTATIONS, PACK SIZES, MARKETING AUTHORISATION NUMBER(S) & BASIC especially during first months. Consider prompt interruption/discontinuation of Symtuza if NHS COSTS PRESCRIBING INFORMATION evidence of new/worsening liver dysfunction. Nephrotoxicity: potential risk from chronic Abstracts of the 4th Joint Conference of the British HIV ACTIVE INGREDIENT(S): darunavir, cobicistat, emtricitabine, tenofovir alafenamide. exposure to low levels of tenofovir alafenamide. Renal impairment: Cobicistat decreases PRESENTATIONS PACK MARKETING AUTHORISATION BASIC NHS estimated creatinine clearance. -
Ryan White HIV/AIDS Program
Ryan White HIV/AIDS Program Part B Manual U.S. Department of Health and Human Services Health Resources and Services Administration HIV/AIDS Bureau Revised 2015 Ryan White HIV/AIDS Program Part B Manual—Revised 2015 Preface The Ryan White HIV/AIDS Program (RWHAP) Part B Manual is for RWHAP Part B Program Directors and staff and others interested in the RWHAP Part B Program. The Ryan White HIV/AIDS Program is administered in the Federal government by the Health Resources and Services Administration (HRSA), an Operating Division within the U.S. Department of Health and Human Services (HHS). The RWHAP Part B Program awards grants to assist States and Territories in developing and/or enhancing access to a comprehensive continuum of high quality HIV care and treatment for low-income people living with HIV (PLWH). Each State and Territory operates a RWHAP Part B program, including an AIDS Drug Assistance Program (ADAP). RWHAP Part B programs, as well as the ADAPs, vary significantly in their administrative structures and the mechanisms used to ensure access to HIV care and to make HIV/AIDS medications available to eligible individuals living with HIV. This Manual is designed to serve as: • An orientation guide for new RWHAP Part B staff, with sections explaining how the RWHAP Part B and ADAPs are structured at the Federal and State level, and the key issues and strategies used by the RWHAP Part B and ADAPs to broaden access to HIV/AIDS care and treatment to persons in need. • A reference document for RWHAP Part B staff on legislative and program requirements. -
Ryan White CARE Act, Donna Elaine Sweet, MD, MACP, AAHIVS the Nation Embarks on Historic E Xecutive Director Health Care Reform James Friedman, MHA by HOLLY A
The AmericAn AcAdemy of HiV medicine HIV® S p ecIalist Ryan Patient Care, PraCtiCe ManageMent & Professional Development inforMation for HIV Care ProviDers Summer 2010 www.aahivm.org White Lives Saved, the Battle Continues 340B Pharmacies 3 Health Care Reform & HIV 4 National HIV/AIDS Strategy 8 Deborah Parham Hopson 11 By JaMes M. friedman, MHa, ExEcutivE dirEctor, aahivm LetteR fRom tHe DIR e c t OR Secretary Sebelius and President obama making a Commitment to the HIV Workforce n June, Health and Human Services panded routine testing, is a recipe for disaster. (HHS) Secretary Kathleen Sebelius and Additionally, the anticipated influx of patients Health Resources and Services Admin- resulting from the implementation of many of istration Administrator Mary Wakefield the health reform provisions in 2014 must be Iannounced a one-time investment of $250 mil- met with new and qualified providers. lion to strengthen the primary care workforce. HIV/AIDS workforce continues to be a This new money came from a $500 million high policy priority for the Academy. We have Prevention and Public Health Fund which was engaged Congress and advocated for the ex- a part of the new health reform law that passed pansion of the National Health Service Corps, this year (The Patient Protection and Afford- James Friedman and are pleased to see that the new health re- able Care Act). This investment is not to be confused with form law provides for growth in both funding and capacity the $1.3 billion authorized over five years for the National of the Corps in the future —a move that will certainly help Health Service Corps (also in the health reform bill), or the increase the number of HIV practitioners. -
Antiretroviral Price Reductions
UNTANGLING THE WEB OF ANTIRETROVIRAL PRICE REDUCTIONS 18th Edition – July 2016 www.msfaccess.org PREFACE In this report, we provide an update on the key facets of HIV treatment access. It includes the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line and salvage regimens, and a summary of the opportunities for – and threats to – expanding access to affordable antiretroviral therapy (ART). There is a table with information on ARVs, including quality assurance, manufacturers and pricing on pages 55 to 57. THE MSF ACCESS CAMPAIGN In 1999, on the heels of Médecins Sans Frontières (MSF) being awarded the Nobel Peace Prize – and largely in response to the inequalities surrounding access to HIV/AIDS treatment between rich and poor countries – MSF launched the Campaign for Access to Essential Medicines. Its sole purpose has been to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostics and vaccines for patients in MSF programmes and beyond. www.msfaccess.org MSF AND HIV Médecins Sans Frontières (MSF) began providing antiretroviral therapy to a small number of people living with HIV/AIDS in 2000 in projects in Thailand, South Africa and Cameroon. At the time, treatment for one person for one year cost more than US$10,000. With increased availability of low-cost, quality antiretroviral drugs (ARVs), MSF provides antiretroviral treatment to 240,100 people in 18 countries, implements treatment strategies to reach more people earlier in their disease progression, and places people living with HIV at the centre of their care. -
Expenditures for the Care of HIV-Infected Patients in Rural Areas in China's Antiretroviral Therapy Programs
UCLA UCLA Previously Published Works Title Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs Permalink https://escholarship.org/uc/item/7f0435d4 Journal BMC Medicine, 9(1) ISSN 1741-7015 Authors Zhou, Feng Kominski, Gerald F Qian, Han-Zhu et al. Publication Date 2011-01-17 DOI http://dx.doi.org/10.1186/1741-7015-9-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Zhou et al. BMC Medicine 2011, 9:6 http://www.biomedcentral.com/1741-7015/9/6 RESEARCHARTICLE Open Access Expenditures for the care of HIV-infected patients in rural areas in China’s antiretroviral therapy programs Feng Zhou1*, Gerald F Kominski2, Han-Zhu Qian3, Jiansheng Wang4, Song Duan5, Zhiwei Guo6, Xinping Zhao7 Abstract Background: The Chinese government has provided health services to those infected by the human immunodeficiency virus (HIV) under the acquired immunodeficiency syndrome (AIDS) care policy since 2003. Detailed research on the actual expenditures and costs for providing care to patients with AIDS is needed for future financial planning of AIDS health care services and possible reform of HIV/AIDS-related policy. The purpose of the current study was to determine the actual expenditures and factors influencing costs for untreated AIDS patients in a rural area of China after initiating highly active antiretroviral therapy (HAART) under the national Free Care Program (China CARES). Methods: A retrospective cohort study was conducted in Yunnan and Shanxi Provinces, where HAART and all medical care are provided free to HIV-positive patients. Health expenditures and costs in the first treatment year were collected from medical records and prescriptions at local hospitals between January and June 2007. -
State of the Art: AIDS and ECONOMICS
IAEN ~ International AIDS-Economics Network State of the Art: AIDS AND ECONOMICS July 2002 This document features papers written by: Peter Badcock-Walters Tony Barnett Stefano Bertozzi Lori Bollinger Lisa DeMaria Lia Fernald Steven Forsythe P. Hale S.M. Hammer Ishrat Husain Robert Greener Juan-Pablo Gutierrez M.D. Kazatchkine Lilani Kumaranayake Bill McGreevey Jean-Paul Moatti Ken Morrison I. N’Doye Shanti Noreiga Majorie Opuni John Stover Beena Varghese Alan Whiteside Editor: Steven Forsythe Director of Planning and Finance, HIV/AIDS Sponsored by: POLICY Project, and Merck & Co., Inc. POLICY Project State of the Art: AIDS AND ECONOMICS July 2002 Editor: Steven Forsythe Director of Planning and Finance, HIV/AIDS The POLICY Project Executive Summary i Acknowledgements The POLICY Project wishes to thank the many authors who wrote the chapters in this document. We also wish to thank Merck & Co. Inc, which has made a con- tribution specifically towards the repro- duction of this document. In addition to this hard copy, Merck’s contribution also made it possible for this document to be reproduced electronically on a CD and on the International AIDS and Economics Network (IAEN) website, www.iaen.org. All of the authors voluntarily contributed their time, effort, and creative ideas in or- der to make this document possible. The opinions expressed herein are those of the authors and do not necessarily reflect the views of any of the contributing agencies. The POLICY Project is implemented by The Futures Group International in col- laboration with Research Triangle Insti- tute and the Centre for Development and Population Activities, with funding from the United States Agency for International Development. -
Pepfar 2017 Annual Report
PEPFAR 2018 ANNUAL REPORT TO CONGRESS 15 YEARS OF SAVING LIVES THROUGH AMERICAN GENEROSITY AND PARTNERSHIP THE UNITED STATES PRESIDENT’S EMERGENCY PLAN FOR AIDS RELIEF 15 Years of Bipartisan Leadership 2018 Annual Report to Congress CONTENTS Executive Summary . 4 Accelerating Access to HIV Treatment . 76 The World Before PEPFAR . 11 Rates of Adherence and Retention . 78 Accelerating Progress Toward Epidemic Control . 13 HIV/AIDS Guidance – New Guidelines: Impact on the Epidemic and Policy Change as Part of Delivering on the Vision . 14 Shared Responsibility . 80 Key Remaining Challenges . 24 HIV Burden and Treatment Response . 86 PEPFAR Strategy for Accelerating Progress Supportive Care . 91 Toward Epidemic Control . 27 Ensuring Pediatric Treatment and Psychosocial Conclusion . 28 Support So Children Can Thrive . 92 Increasing the Impact and Cost-Effectiveness of Addressing Tuberculosis/HIV Co-Infection . 99 Every Dollar Invested . 30 Leveraging Partnerships for Sustainability . 102 How PEPFAR Harnesses Data for Maximizing Cost Effectiveness and Impact: Controlling the Building a Safer, More Secure World Through HIV/AIDS Pandemic . 32 Strategic PEPFAR Health Investments . 104 How PEPFAR Documents Results . 35 Driving a Sustainability Agenda with Country Partners . 106 Global Trends in New HIV Infections . 38 Table 6: Operationalizing Sustainability . 107 HIV Infections Averted Due to PEPFAR and Global HIV Response . 45 The Sustainability Index and Dashboard – A Road Map to Transfer Responsibility . 109 Validating the Models . 45 Sustainable Financing as a Key Priority . 109 Global Prevalence: Refining PEPFAR’s Impact and Progress Toward Epidemic Control and Building a Data Platform . 110 Implications of Future Costs for a Sustained HIV/AIDS Response . 47 Table 6 . -
HIV MEDICINE Published on Behalf of the British HIV Association and the European AIDS Clinical Society
HIV MEDICINE Published on behalf of the British HIV Association and the European AIDS Clinical Society Editors Brian Gazzard, UK HINARI: Access to this journal is available free online within institutions Jens Lundgren, Denmark in the developing world through the HINARI initiative with the WHO. For information, visit www.who.int/hinari/en/ Editorial Board Wiley is a founding member of the UN-backed HINARI, AGORA, and OARE José Gatell, Spain initiatives. They are now collectively known as Research4Life, making online scientific content available free or at nominal cost to researchers in developing Margaret Johnson, UK countries. Please visit Wiley’s Content Access – Corporate Citizenship site: Jürgen Rockstroh, Germany http://www.wiley.com/WileyCDA/Section/id-390082.html Georg Behrens, Germany Ian Williams, UK Publisher and Business Correspondence Editorial Panel HIV Medicine is published by John Wiley & Sons Ltd: 9600 Francisco Antunes, Portugal Jeff Lazarus, Denmark Garsington Road, Oxford OX4 2DQ, UK. Tel: +44 (0)1865 776868, Fax: Jose Arribas, Spain Adriano Lazzarin, Italy +44 (0)1865 714591. Blackwell Publishing was acquired by John Wiley & Jason Baker, USA Paddy Mallon, Dublin Sons in February 2007. Wiley’s Corporate Citizenship initiative seeks to address the environmental, Georg Behrens, Germany Esteban Martinez, Spain social, economic, and ethical challenges faced in our business and which Jordi Blanch, Spain Frank Miedema, Netherlands are important to our diverse stakeholder groups. Since launching the Stéphane Blanche, France José M Miró, Spain initiative, we have focused on sharing our content with those in need, Ray Brettle, UK Amanda Mocroft, London enhancing community philanthropy, reducing our carbon impact, creating Françoise Brun-Vézinet, France Jean-Michel Molina, France global guidelines and best practices for paper use, establishing a vendor Alexandra Calmy, Switzerland Fiona Mulcahy, Ireland code of ethics, and engaging our colleagues and other stakeholders in our Richard Chaisson, USA Robert Murphy, USA efforts. -
Costs of Streamlined HIV Care Delivery in Rural Ugandan and Kenyan Clinics in the SEARCH Study Starley B
Costs of streamlined HIV care delivery in rural Ugandan and Kenyan clinics in the SEARCH Study Starley B. Shadea,b, Thomas Osmandb, Alex Luoa, Ronald Ainec, Elly Assurahd, Betty Mwebazac, Daniel Mwaie, Asiphas Owaraganisec, Florence Mwangwac, James Ayiekod, Douglas Blackf, Lillian B. Brownf, Tamara D. Clarkf, Dalsone Kwarisiimac, Harsha Thirumurthyg, Craig R. Cohenh, Elizabeth A. Bukusid, Edwin D. Charleboisb, Laura Balzeri, Moses R. Kamyaj, Maya L. Petersenk, Diane V. Havlirf and Vivek Jainf Objectives/design: As antiretroviral therapy (ART) rapidly expands in sub-Saharan Africa using new efficient care models, data on costs of these approaches are lacking. We examined costs of a streamlined HIV care delivery model within a large HIV test- and-treat study in Uganda and Kenya. Methods: We calculated observed per-person-per-year (ppy) costs of streamlined care in 17 health facilities in SEARCH Study intervention communities (NCT: 01864603) via micro-costing techniques, time-and-motion studies, staff interviews, and administrative records. Cost categories included salaries, ART, viral load testing, recurring goods/ services, and fixed capital/facility costs. We then modeled costs under three increas- ingly efficient scale-up scenarios: lowest-cost ART, centralized viral load testing, and governmental healthcare worker salaries. We assessed the relationship between com- munity-specific ART delivery costs, retention in care, and viral suppression. Results: Estimated streamlined HIV care delivery costs were $291/ppy. ART ($117/ppy for TDF/3TC/EFV [40%]) and viral load testing ($110/ppy for 2 tests/year [39%]) dominated costs versus salaries ($51/ppy), recurring costs ($5/ppy), and fixed costs ($7/ppy). Optimized ART scale-up with lowest-cost ART ($100/ppy), annual viral load testing ($24/ppy), and govern- mental healthcare salaries ($27/ppy), lowered streamlined care cost to $163/ppy. -
Statement on the Anniversary of the Founding of Turkey Remarks On
Oct. 30 / Administration of Barack Obama, 2009 democracy, and our people have forged a and our country, and they continue to play a strong and lasting partnership that is grounded key role in shaping the direction of our Nation. in these shared values. Czech Americans trace their roots back to before our country was NOTE: This statement was released by the Of- founded, they have enriched our communities fice of the Press Secretary on October 30. Statement on the Anniversary of the Founding of Turkey October 29, 2009 The people of the United States join the come many shared challenges. Turkish Ameri- people of Turkey in celebrating the anniversa- cans help to forge the bonds that join our na- ry of the founding of the Republic of Turkey. tions in friendship, and they continue to con- The friendship between our nation is strong, tribute to our society in a wide range of field, and our alliance is enduring. More than 50 including arts, athletics, education, business, years ago, the United States and Turkey began medicine, and science. a partnership based on shared values and mu- tual respect, a partnership and friendship that NOTE: This statement was released by the Of- has deepened over the years as we have over- fice of the Press Secretary on October 30. Remarks on Signing the Ryan White HIV/AIDS Treatment Extension Act of 2009 October 30, 2009 The President. Good morning, everybody. contracted HIV/AIDS from a transfusion. Audience members. Good morning. Doctors assured people that Ryan White The President. We often speak about AIDS posed no risk to his classmates or his commu- as if it’s going on somewhere else, and for nity, but ignorance was still widespread.